Phase II trial of vinblastine in previously treated patients with ovarian cancer: A southwest oncology group study

E. A. Surwit, David S Alberts, R. V. O'Toole, V. Graham, E. V. Hannigan, R. L. Stephens, J. G. Boutselis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Sixty-eight patients with relapsing, epithelial type ovarian carcinoma were entered into a Phase II study of vinblastine. Vinblastine was administered as a continuous intravenous infusion over 5 days at a starting dose of 1.7 mg/m2/day every 3 weeks. There were 44 fully evaluable and 6 partially evaluable patients. Forty-one of these patients had had only one prior treatment regimen. Grade 3 or 4 leukopenia occurred in 12 patients (24%), but Grade 3 or 4 thrombocytopenia occurred in only 2 patients. There were two clinical complete responses of 18- and 36-week durations and one partial response of 6 weeks for an overall response rate of 7%. We conclude that vinblastine, administered in optimal dose and schedule, has little clinical activity in previously treated patients with ovarian cancer.

Original languageEnglish (US)
Pages (from-to)14-19
Number of pages6
JournalGynecologic Oncology
Volume28
Issue number1
DOIs
StatePublished - 1987

Fingerprint

Vinblastine
Ovarian Neoplasms
Leukopenia
Intravenous Infusions
Appointments and Schedules
Carcinoma

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Phase II trial of vinblastine in previously treated patients with ovarian cancer : A southwest oncology group study. / Surwit, E. A.; Alberts, David S; O'Toole, R. V.; Graham, V.; Hannigan, E. V.; Stephens, R. L.; Boutselis, J. G.

In: Gynecologic Oncology, Vol. 28, No. 1, 1987, p. 14-19.

Research output: Contribution to journalArticle

Surwit, E. A. ; Alberts, David S ; O'Toole, R. V. ; Graham, V. ; Hannigan, E. V. ; Stephens, R. L. ; Boutselis, J. G. / Phase II trial of vinblastine in previously treated patients with ovarian cancer : A southwest oncology group study. In: Gynecologic Oncology. 1987 ; Vol. 28, No. 1. pp. 14-19.
@article{2eb878dee71d4419ae2536e9bbc2f76d,
title = "Phase II trial of vinblastine in previously treated patients with ovarian cancer: A southwest oncology group study",
abstract = "Sixty-eight patients with relapsing, epithelial type ovarian carcinoma were entered into a Phase II study of vinblastine. Vinblastine was administered as a continuous intravenous infusion over 5 days at a starting dose of 1.7 mg/m2/day every 3 weeks. There were 44 fully evaluable and 6 partially evaluable patients. Forty-one of these patients had had only one prior treatment regimen. Grade 3 or 4 leukopenia occurred in 12 patients (24{\%}), but Grade 3 or 4 thrombocytopenia occurred in only 2 patients. There were two clinical complete responses of 18- and 36-week durations and one partial response of 6 weeks for an overall response rate of 7{\%}. We conclude that vinblastine, administered in optimal dose and schedule, has little clinical activity in previously treated patients with ovarian cancer.",
author = "Surwit, {E. A.} and Alberts, {David S} and O'Toole, {R. V.} and V. Graham and Hannigan, {E. V.} and Stephens, {R. L.} and Boutselis, {J. G.}",
year = "1987",
doi = "10.1016/S0090-8258(87)80003-3",
language = "English (US)",
volume = "28",
pages = "14--19",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Phase II trial of vinblastine in previously treated patients with ovarian cancer

T2 - A southwest oncology group study

AU - Surwit, E. A.

AU - Alberts, David S

AU - O'Toole, R. V.

AU - Graham, V.

AU - Hannigan, E. V.

AU - Stephens, R. L.

AU - Boutselis, J. G.

PY - 1987

Y1 - 1987

N2 - Sixty-eight patients with relapsing, epithelial type ovarian carcinoma were entered into a Phase II study of vinblastine. Vinblastine was administered as a continuous intravenous infusion over 5 days at a starting dose of 1.7 mg/m2/day every 3 weeks. There were 44 fully evaluable and 6 partially evaluable patients. Forty-one of these patients had had only one prior treatment regimen. Grade 3 or 4 leukopenia occurred in 12 patients (24%), but Grade 3 or 4 thrombocytopenia occurred in only 2 patients. There were two clinical complete responses of 18- and 36-week durations and one partial response of 6 weeks for an overall response rate of 7%. We conclude that vinblastine, administered in optimal dose and schedule, has little clinical activity in previously treated patients with ovarian cancer.

AB - Sixty-eight patients with relapsing, epithelial type ovarian carcinoma were entered into a Phase II study of vinblastine. Vinblastine was administered as a continuous intravenous infusion over 5 days at a starting dose of 1.7 mg/m2/day every 3 weeks. There were 44 fully evaluable and 6 partially evaluable patients. Forty-one of these patients had had only one prior treatment regimen. Grade 3 or 4 leukopenia occurred in 12 patients (24%), but Grade 3 or 4 thrombocytopenia occurred in only 2 patients. There were two clinical complete responses of 18- and 36-week durations and one partial response of 6 weeks for an overall response rate of 7%. We conclude that vinblastine, administered in optimal dose and schedule, has little clinical activity in previously treated patients with ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023205632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023205632&partnerID=8YFLogxK

U2 - 10.1016/S0090-8258(87)80003-3

DO - 10.1016/S0090-8258(87)80003-3

M3 - Article

C2 - 3653765

AN - SCOPUS:0023205632

VL - 28

SP - 14

EP - 19

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -